WASHINGTON - The successful development of two mRNA vaccines against Covid-19, at the lightning-fast speed of barely a year, was hailed by analysts as a triumph for America’s biotechnology industry, and a sign that the superpower continued to lead the world in the sector.
In contrast, China’s Sinovac jabs, which use more traditional vaccine technology, have been shown to be less effective in preventing severe illness and require more doses for a similar level of protection.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
